DexCom, Inc. $DXCM Shares Purchased by Waverly Advisors LLC

Waverly Advisors LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 18.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,920 shares of the medical device company’s stock after purchasing an additional 10,187 shares during the period. Waverly Advisors LLC’s holdings in DexCom were worth $4,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in DexCom by 6,567.7% in the second quarter. California State Teachers Retirement System now owns 39,176,552 shares of the medical device company’s stock valued at $2,638,541,000 after purchasing an additional 38,588,991 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after buying an additional 1,515,702 shares during the period. Geode Capital Management LLC raised its stake in shares of DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after buying an additional 42,411 shares during the period. Norges Bank purchased a new position in shares of DexCom during the 4th quarter valued at approximately $483,356,000. Finally, Invesco Ltd. lifted its position in shares of DexCom by 14.8% during the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after buying an additional 686,228 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the stock a “buy” rating in a report on Monday, August 3rd. Barclays reiterated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. UBS Group set a $96.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada upped their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, Bank of America decreased their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $88.71.

DexCom Price Performance

DexCom stock opened at $84.51 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The firm has a market capitalization of $31.89 billion, a price-to-earnings ratio of 33.40, a PEG ratio of 1.41 and a beta of 1.42. The company has a fifty day simple moving average of $82.51 and a 200-day simple moving average of $72.73. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the firm posted $0.48 earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,777 shares of company stock worth $4,950,714 in the last quarter. Insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.